PCM
REGN icon

Parsons Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Parsons Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100
Closed -$45K – 487
2015
Q1 		$45K Buy
+100
New +$42.4K 0.01% 485

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Parsons Capital Management's REGN Position: Q2 2015 in Review

Parsons Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2015, closing a stake of 100 shares — an estimated $45K sold.

Parsons Capital Management first reported a position in REGN in Q1 2015 and held it in 1 quarter. The position peaked at $45K in Q1 2015. 540 funds tracked by Wall St. Rank hold REGN as of Q2 2015.

  • Parsons Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Parsons Capital Management sold 100 Regeneron Pharmaceuticals shares in Q2 2015, an estimated $45K.
  • Parsons Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Parsons Capital Management's Regeneron Pharmaceuticals position peaked at $45K in Q1 2015.
  • 540 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2015.

Based on Parsons Capital Management's 13F filing for Q2 2015, filed 5 Aug 2015.